Skip to content

TG Therapeutics

US · TGTX #1638 by market cap Listed 1970
63.34 -1.54 -2.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Founded
1993
CEO
Mr. Michael S. Weiss
Employees
399
Headquarters
Morrisville, North Carolina, United States of America
Fiscal year end
12-31
Website
tgtherapeutics.com

Company profile

Exchange
US
Symbol
TGTX
Market-cap rank
#1638
Listing date
1970-01-01
Market cap
9.57B
Float cap
9.16B
Shares out
151.15M
Float shares
144.54M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.

TG Therapeutics discussion 0 comments

Add a comment